Neurocrine Biosciences (NBIX) : Blue Jay Capital Management scooped up 156,450 additional shares in Neurocrine Biosciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 356,510 shares of Neurocrine Biosciences which is valued at $15.6 Million.Neurocrine Biosciences makes up approximately 9.67% of Blue Jay Capital Management’s portfolio.
Other Hedge Funds, Including , Parametric Portfolio Associates boosted its stake in NBIX in the latest quarter, The investment management firm added 24,558 additional shares and now holds a total of 47,845 shares of Neurocrine Biosciences which is valued at $2.1 Million.Profund Advisors reduced its stake in NBIX by selling 10,859 shares or 18.76% in the most recent quarter. The Hedge Fund company now holds 47,017 shares of NBIX which is valued at $2 Million. Neurocrine Biosciences makes up approx 0.10% of Profund Advisors’s portfolio. Hood River Capital Management added NBIX to its portfolio by purchasing 135,555 company shares during the most recent quarter which is valued at $5.8 Million. Neurocrine Biosciences makes up approx 0.80% of Hood River Capital Management’s portfolio. Checchi Capital Advisers added NBIX to its portfolio by purchasing 99 company shares during the most recent quarter which is valued at $4,244.Public Employees Retirement Association Of Colorado reduced its stake in NBIX by selling 269 shares or 1.25% in the most recent quarter. The Hedge Fund company now holds 21,268 shares of NBIX which is valued at $969,395. Neurocrine Biosciences makes up approx 0.01% of Public Employees Retirement Association Of Colorado’s portfolio.
Neurocrine Biosciences closed down -2.21 points or -4.53% at $46.56 with 11,42,981 shares getting traded on Wednesday. Post opening the session at $49.06, the shares hit an intraday low of $46.01 and an intraday high of $49.44 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Neurocrine Biosciences reported $-0.22 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.29. The company had revenue of $15.00 million for the quarter, compared to analysts expectations of $15.43 million. The company’s revenue was down -24.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.01 EPS.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.